Methamphetamine enhances Hepatitis C virus replication in human hepatocytes

Journal of Viral Hepatitis

Volumn 15, Issue 4, 2008, Pages 261-270

  Ye, L ^a,d   Peng, J S ^b   Wang, X ^a   Wang, Y J ^a   Luo, G X ^c   Ho, W Z ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Wuhan Regional Center for Disease Control and Prevention   (China)

^c UNIVERSITY OF KENTUCKY   (United States)

^d WUHAN UNIVERSITY   (China)

Author keywords

Hepatitis C virus; Interferon alpha; IRF 5; Methamphetamine; STAT 1

Indexed keywords

ALPHA INTERFERON; INTERFERON REGULATORY FACTOR 5; METHAMPHETAMINE; RECOMBINANT ALPHA INTERFERON; STAT1 PROTEIN; TRANSCRIPTION FACTOR;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; GENE EXPRESSION REGULATION; HEPATITIS C VIRUS; HOST CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOGENESIS; IN VITRO STUDY; INNATE IMMUNITY; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; RISK FACTOR; VIRUS REPLICATION;

BLOTTING, WESTERN; CELL LINE; DOWN-REGULATION; HEPACIVIRUS; HEPATOCYTES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON REGULATORY FACTORS; INTERFERON-ALPHA; METHAMPHETAMINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STAT1 TRANSCRIPTION FACTOR; VIRUS REPLICATION;

EID: 40149089712     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2007.00940.x     Document Type: Article

References (49)

1. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000 20 (1 1 16.
2. De Francesco R, Migliaccio G. Challenges and successes in developing new therapies for hepatitis C. Nature 2005 436 (7053 953 960.
3. Alter MJ, Kruszon-Moran D, Nainan OV et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999 341 (8 556 562.
4. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003 9 (4 331 338.
5. Scott JD, Gretch DR. Molecular diagnostics of hepatitis C virus infection: a systematic review. JAMA 2007 297 (7 724 732.
6. Hagan H, Thiede H, Des Jarlais DC. HIV/hepatitis C virus co-infection in drug users: risk behavior and prevention. AIDS 2005 19 (Suppl. 3 S199 S207.
7. Day C, Ross J, Dolan K. Hepatitis C-related discrimination among heroin users in Sydney: drug user or hepatitis C discrimination? Drug Alcohol Rev 2003 22 (3 317 321.
8. Smyth BP, Barry J, Keenan E. Irish injecting drug users and hepatitis C: the importance of the social context of injecting. Int J Epidemiol 2005 34 (1 166 172.
9. Alter MJ. Prevention of spread of hepatitis C. Hepatology 2002 5 (Suppl. 1 S93 S98.
10. Williams I. Epidemiology of hepatitis C in the United States. Am J Med 1999 107 (6B 2S 9S.
11. Thomas DL, Vlahov D, Solomon L et al. Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) 1995 74 (4 212 220.
12. Molitor F, Truax SR, Ruiz JD, Sun RK. Association of methamphetamine use during sex with risky sexual behaviors and HIV infection among non-injection drug users. West J Med 1998 168 (2 93 97.
13. Halkitis PN, Parsons JT, Stirratt MJ. A double epidemic: crystal methamphetamine drug use in relation to HIV transmission among gay men. J Homosex 2001 41 (2 17 35.
14. Ellis RJ, Childers ME, Cherner M, Lazzaretto D, Letendre S, Grant I. Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy. J Infect Dis 2003 188 (12 1820 1826.
15. Cherner M, Letendre S, Heaton RK et al. Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine. Neurology 2005 64 (8 1343 1347.
16. Letendre SL, Cherner M, Ellis RJ et al. The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: biological correlates of disease. AIDS 2005 19 (Suppl. 3 S72 S78.
17. Soriano V, Sulkowski M, Bergin C et al. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS 2002 16 (6 813 828.
18. Miller CL, Wood E, Spittal PM et al. The future face of coinfection: prevalence and incidence of HIV and hepatitis C virus coinfection among young injection drug users. J Acquir Immune Defic Syndr 2004 36 (2 743 749.
19. Alter MJ. Hepatitis C virus infection in the United States. J Hepatol 1999 31 (Suppl. 1 88 91.
20. Wada K, Greberman SB, Konuma K, Hirai S. HIV and HCV infection among drug users in Japan. Addiction 1999 94 (7 1063 1069.
21. Hahn JA, Page-Shafer K, Lum PJ, Ochoa K, Moss AR. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology 2001 34 (1 180 187.
22. Gonzales R, Marinelli-Casey P, Shoptaw S, Ang A, Rawson RA. Hepatitis C virus infection among methamphetamine-dependent individuals in outpatient treatment. J Subst Abuse Treat 2006 31 (2 195 202.
23. Cai Z, Zhang C, Chang KS et al. Robust production of infectious hepatitis C virus (HCV) from stably HCV cDNA-transfected human hepatoma cells. J Virol 2005 79 (22 13963 13973.
24. Wakita T, Pietschmann T, Kato T et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005 11 (7 791 796.
25. Mahajan SD, Hu Z, Reynolds JL, Aalinkeel R, Schwartz SA, Nair MP. Methamphetamine modulates gene expression patterns in monocyte derived mature dendritic cells: implications for HIV-1 pathogenesis. Mol Diagn Ther 2006 10 (4 257 269.
26. Melega WP, Cho AK, Harvey D, Lacan G. Methamphetamine blood concentrations in human abusers: application to pharmacokinetic modeling. Synapse 2007 61 (4 216 220.
27. Gjerde H, Hasvold I, Pettersen G, Christophersen AS. Determination of amphetamine and methamphetamine in blood by derivatization with perfluorooctanoyl chloride and gas chromatography/mass spectrometry. J Anal Toxicol 1993 17 (2 65 68.
28. Li Y, Zhang T, Douglas SD et al. Morphine enhances hepatitis C virus (HCV) replicon expression. Am J Pathol 2003 163 (3 1167 1175.
29. Li Y, Zhang T, Ho C, Orange JS, Douglas SD, Ho WZ. Natural killer cells inhibit hepatitis C virus expression. J Leukoc Biol 2004 76 (6 1171 1179.
30. Zhang T, Lin RT, Li Y et al. Hepatitis C virus inhibits intracellular interferon alpha expression in human hepatic cell lines. Hepatology 2005 42 (4 819 827.
31. Nguyen H, Hiscott J, Pitha PM. The growing family of interferon regulatory factors. Cytokine Growth Factor Rev 1997 8 (4 293 312.
32. Mamane Y, Heylbroeck C, Genin P et al. Interferon regulatory factors: the next generation. Gene 1999 237 (1 1 14.
33. Yu Q, Zhang D, Walston M, Zhang J, Liu Y, Watson RR. Chronic methamphetamine exposure alters immune function in normal and retrovirus-infected mice. Int Immunopharmacol 2002 2 (7 951 962.
34. House RV, Thomas PT, Bhargava HN. Comparison of immune functional parameters following in vitro exposure to natural and synthetic amphetamines. Immunopharmacol Immunotoxicol 1994 16 (1 1 21.
35. Poli G, Vicenzi E, Ghezzi S, Lazzarin A. Cytokines in the acquired immunodeficiency syndrome and other infectious diseases. Int J Clin Lab Res 1995 25 (3 128 134.
36. Mbow ML, Eaton-Bassiri A, Glass WG, Del Vecchio AM, Sarisky RT. Small molecule and biologic modulators of the immune response to hepatitis C virus. Mini Rev Med Chem 2006 6 (5 527 531.
37. Davis GL, Esteban-Mur R, Rustgi V et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998 339 (21 1493 1499.
38. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998 339 (21 1485 1492.
39. Velazquez L, Fellous M, Stark GR, Pellegrini S. A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell 1992 70 (2 313 322.
40. O'Shea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 2002 109 (Suppl. 2 S121 S131.
41. Mbow ML, Sarisky RT. What is disrupting IFN-alpha's antiviral activity? Trends Biotechnol 2004 22 (8 395 399.
42. van Boxel-Dezaire AH, Rani MR, Stark GR. Complex modulation of cell type-specific signaling in response to type I interferons. Immunity 2006 25 (3 361 372.
43. Barnes BJ, Moore PA, Pitha PM. Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon alpha genes. J Biol Chem 2001 276 (26 23382 23390.
44. Marie I, Durbin JE, Levy DE. Differential viral induction of distinct interferon-alpha genes by positive feedback through interferon regulatory factor-7. EMBO J 1998 17 (22 6660 6669.
45. Au WC, Pitha PM. Recruitment of multiple interferon regulatory factors and histone acetyltransferase to the transcriptionally active interferon a promoters. J Biol Chem 2001 276 (45 41629 41637.
46. Barnes BJ, Kellum MJ, Field AE, Pitha PM. Multiple regulatory domains of IRF-5 control activation, cellular localization, and induction of chemokines that mediate recruitment of T lymphocytes. Mol Cell Biol 2002 22 (16 5721 5740.
47. Honda K, Taniguchi T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol 2006 6 : 644 658.
48. Zein NN. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev 2000 13 (2 223 235.
49. Simmonds P, Bukh J, Combet C et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005 42 (4 962 973.